{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:54:29Z","timestamp":1754261669141},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/internalmedicine.52.9347","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T23:36:47Z","timestamp":1375313807000},"page":"1681-1686","source":"Crossref","is-referenced-by-count":4,"title":["Status of Lipid Management Using Lifestyle Modification in Japanese Adults: An Analysis of the 2009 Japan Society of Ningen Dock Database"],"prefix":"10.2169","volume":"52","author":[{"given":"Eiko","family":"Takahashi","sequence":"first","affiliation":[{"name":"Japan Society of Ningen Dock, Academic Committee, Japan"},{"name":"Department of Clinical Health Science, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Health Science, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yamakado","sequence":"additional","affiliation":[{"name":"Japan Society of Ningen Dock, Academic Committee, Japan"},{"name":"Mitsui Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and risk of coronary heart disease. The Framingham Study. Ann Intern Med 74: 1-12, 1971.","DOI":"10.7326\/0003-4819-74-1-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823-2828, 1986.","DOI":"10.1001\/jama.1986.03380200061022"},{"key":"3","unstructured":"3. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 256: 2835-2838, 1986."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97: 1440-1445, 1998.","DOI":"10.1161\/01.CIR.97.15.1440"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357, 1998.","DOI":"10.1056\/NEJM199811053391902"},{"key":"7","unstructured":"7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS: Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622, 1998."},{"key":"8","unstructured":"8. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368: 1155-1163, 2006."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. National Cholesterol Education Program. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 148: 36-69, 1988.","DOI":"10.1001\/archinte.1988.00380010040006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89: 1333-1445, 1994.","DOI":"10.1161\/01.CIR.89.3.1333"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.","DOI":"10.1001\/jama.285.19.2486"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. National Cholesterol Education Program Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421, 2002.","DOI":"10.1161\/circ.106.25.3143"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239, 2004.","DOI":"10.1161\/01.CIR.0000133317.49796.0E"},{"key":"14","unstructured":"14. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31: 811-822, 2008."},{"key":"15","unstructured":"15. Catapano AL, Reiner Z, De Backer G, et al. for the ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. ESC\/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217 (Suppl 1): S1-S44, 2011."},{"key":"16","unstructured":"16. Hata Y, Mabuchi H, Saito Y, et al. Guideline for diagnosis and treatment of hyperlipidemia in adults. Domyakukoka 25: 1-34, 1997 (in Japanese)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Matsuzaki M, Kita T, Mabuchi H, et al. for the J-LIT Study Group, Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66: 1087-1095, 2002.","DOI":"10.1253\/circj.66.1087"},{"key":"18","unstructured":"18. Mabuchi H, Kita T, Matsuzaki M, et al. for the J-LIT Study Group, Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66: 1096-1100, 2002."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hata Y, Mabuchi H, Saito Y, et al. for the Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults. J Atheroscler Thromb 9: 1-27, 2002.","DOI":"10.5551\/jat.9.1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14: 45-50, 2007.","DOI":"10.5551\/jat.14.45"},{"key":"21","unstructured":"21. JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Japan Atherosclerosis Society, Tokyo, Japan, 2012 (in Japanese)."},{"key":"22","unstructured":"22. Teramoto T, Kashiwagi A, Mabuchi H. Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for diagnosis and treatment of hyperlipidemia in Japanese adult: A study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res 66: 80-95, 2005."},{"key":"23","unstructured":"23. Takahashi E, Moriyama K, Yamakado M. Status of dyslipidemia treatment in Japanese adults: analysis of the 2009 Japan Society of Ningen Dock database. Intern Med 52: 295-301, 2013."},{"key":"24","unstructured":"24. Takahashi E. Database Creation Subcommittee of Japan Society of Ningen Dock. Report of the Database Creation Subcommittee : Pilot Study. Ningen Dock 26: 799-847, 2012."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ishikawa T, Mizuno K, Nakaya N, et al. for the MEGA Study Group. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circ J 72: 1576-1582, 2008.","DOI":"10.1253\/circj.CJ-08-0095"},{"key":"27","unstructured":"27. Okada M, Miida T, Hama H, et al. Possible risk factors of carotid artery atherosclerosis in the Japanese population: a primary prevention study in non-diabetic subjects. Intern Med 39: 362-368, 2000."},{"key":"28","unstructured":"28. Kurihara S, Douzono T, Kawakita K, Fijita S, Nachi S, Nagasaka Y. A large-scale, prospective post-marketing surveillance of Pitavastatin. Jpn Pharmacol Ther 35: 9-40, 2007."},{"key":"29","unstructured":"29. Teramoto T. Atorvastatin Lipid loWering Assessment surveY in patientS with hypercholesterolemia (ALWAYS). Ther Res 32: 1587-1603, 2011."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/15\/52_52.9347\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:49:29Z","timestamp":1621446569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/15\/52_52.9347\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.52.9347","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}